Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Conformetrix and AstraZeneca Sign Collaborative Agreement – First Collaborative Deal for Conformetrix

April 16, 2012

MANCHESTER and LONDON, England, April 16, 2012 /PRNewswire/ –

Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca
announced today that they have signed a research collaboration agreement under which
Conformetrix’s proprietary NMR-based technology will be applied across AstraZeneca’s
pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.

Conformetrix’s technology determines accurate three-dimensional structures – or
conformations – of drug molecules in their bioactive states. This is achieved without the
need for traditional structural information regarding the protein target of each drug and
provides researchers with valuable information on how development-stage compounds are
likely to interact with their targets. This new information should improve the efficiency
and quality of the lead identification, lead optimisation and candidate selection stages
of drug discovery programmes. Under the terms of the two-year collaboration, the
technology will also be used to determine the bioactive conformations of naturally
occurring ligands as templates for drug library enhancement and hit identification.

Commenting on today’s news, Conformetrix’s CEO, Dr Sam Williams, said, ‘Conformetrix
is delighted that its first collaborative deal is with AstraZeneca, a company with a
strong reputation in innovative science-led R&D. We believe that this deal provides
important validation of our technology, which improves the quality and efficiency of drug
discovery, reducing the number of molecules needed to find a drug and enhancing the
likelihood of clinical success. The Conformetrix team is looking forward to working with
our new partner on this exciting programme.’

Mike Snowden, Vice President and Head of Discovery Sciences, AstraZeneca, said: “We
are excited to be working with Conformetrix. We believe their technology will provide a
powerful addition to our hit identification and lead optimisation approaches, supporting
our strategic objectives to improve the quality and choice of candidate compounds for our
early pipeline.”

In addition to an undisclosed upfront payment, Conformetrix will receive research
funding and be eligible for milestones as certain targets are met. The discovery programme
will be managed by a joint AstraZeneca-Conformetrix research team.

About Conformetrix Ltd

Conformetrix is a Manchester, UK-based company focused on optimising drug discovery
and design. It was founded in 2008 as a spin-out from the University of Manchester. The
company uses its NMR-based technology to solve the dynamic 3D structures of a broad range
of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since
Conformetrix’s NMR technology shows what shapes molecules adopt when they are active, it
provides high-quality templates for drug discovery and design, and valuable information
for drug candidate optimisation. In addition, the data is generated faster and more
cheaply than by standard techniques such as X-ray crystallography. Conformetrix has solved
structures for several large pharmaceutical companies, as well as developing proprietary
drug programmes, and has been funded since inception by specialist life science investor
Aquarius Equity Partners. For more information, please go to http://www.conformetrix.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary
focus on the discovery, development and commercialisation of prescription medicines for
gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and
infectious disease. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information please visit:

http://www.astrazeneca.com

        For further information please contact:
        Conformetrix Ltd
        Sam Williams, CEO, +44(0)7881-588947
        Emma Palmer Foster, Strategic Communications Consultant, +44(0)7880-787185
        communications@conformetrix.com

        AstraZeneca
        Laura Woodin, Media Relations, +1-302-885-1087

SOURCE Conformetrix Ltd


Source: PR Newswire